These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
675 related articles for article (PubMed ID: 11371143)
1. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143 [TBL] [Abstract][Full Text] [Related]
2. Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients. Marec-Berard P; Blay JY; Schell M; Buclon M; Demaret C; Ray-Coquard I J Clin Oncol; 2003 Nov; 21(22):4235-8. PubMed ID: 14615453 [TBL] [Abstract][Full Text] [Related]
3. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Dangsuwan P; Manchana T Gynecol Oncol; 2010 Mar; 116(3):522-5. PubMed ID: 20051288 [TBL] [Abstract][Full Text] [Related]
4. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology. Oskay-Ozcelik G; Chekerov R; Sommer H; Keil E; Einenkel J; Pfisterer J; Lorenz-Schlüter C; Lichtenegger W; Camara O; Sehouli J Gynecol Oncol; 2010 Mar; 116(3):317-22. PubMed ID: 19959213 [TBL] [Abstract][Full Text] [Related]
5. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987 [TBL] [Abstract][Full Text] [Related]
6. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Dunphy FR; Dunleavy TL; Harrison BR; Boyd JH; Varvares MA; Dunphy CH; Rodriguez JJ; McDonough EM; Minster JR; McGrady MD Cancer; 1997 Apr; 79(8):1623-8. PubMed ID: 9118049 [TBL] [Abstract][Full Text] [Related]
7. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784 [TBL] [Abstract][Full Text] [Related]
8. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275 [TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721 [TBL] [Abstract][Full Text] [Related]
10. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gronlund B; Høgdall C; Hansen HH; Engelholm SA Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424 [TBL] [Abstract][Full Text] [Related]
11. Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study. Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Colombo N; Fanucchi A; Chiudinelli F; Lapresa M; Maria Ferrero A Gynecol Oncol; 2005 Jul; 98(1):118-23. PubMed ID: 15913740 [TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927 [TBL] [Abstract][Full Text] [Related]
13. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S; Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496 [TBL] [Abstract][Full Text] [Related]
14. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838 [TBL] [Abstract][Full Text] [Related]
16. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799 [TBL] [Abstract][Full Text] [Related]
17. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169 [TBL] [Abstract][Full Text] [Related]
18. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas]. Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068 [TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486 [TBL] [Abstract][Full Text] [Related]
20. Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer. Kietpeerakool C; Tiyayon J; Suprasert P; Kanjanavanit R; Srisomboon J J Med Assoc Thai; 2006 Nov; 89(11):1805-10. PubMed ID: 17205858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]